RSS

Archivi categoria: anemia

The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach – American Journal of Kidney Diseases

Erythropoiesis-stimulating agents (ESAs) have been used to manage anemia in chronic kidney disease (CKD) to reduce transfusion requirements and anemia symptoms. Lack of objective benefit of normalizing hemoglobin (Hb) levels and increased evidence of ESA-induced complications in persons with anemia has resulted in clinicians generally attempting to maintain Hb levels in the 10- to 11-g/dL range. In 2000, concerns in patients with cancer arose attributable to associations of ESA use with increased mortality, thrombotic complications, and cerebrovascular accidents led to a change in US Food and Drug Administration oncology guidelines regarding limitation of ESA use for chemotherapy-induced anemia.

Sorgente: The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach – American Journal of Kidney Diseases

 

Non-Dialysis CKD Patients With Anemia Have More CVD, Worse QoL – Renal and Urology News

Sorgente: Non-Dialysis CKD Patients With Anemia Have More CVD, Worse QoL – Renal and Urology News

 
Lascia un commento

Pubblicato da su 28 giugno 2017 in anemia, malattie renali

 

Most Cost-Effective Hb Target in Anemic CKD Patients Identified –

Anemia treatment is most cost-effective when targeting a specific hemoglobin level, research suggests.

QALYs increased to 4.63 for a target of 10 g/dL and to 4.75 for a target of 10.5 g/dL or 11 g/dL. “Any treatment target above 11 g/dL increased medical costs and decreased QALYs,” the investigators wrote.

Sorgente: Most Cost-Effective Hb Target in Anemic CKD Patients Identified – Renal and Urology News

 

Which ESA Is Safer in Chronic Kidney Disease Patients? – EPO

Which ESA Is Safer in Chronic Kidney Disease Patients? –.

 
Lascia un commento

Pubblicato da su 20 febbraio 2015 in anemia, malattie renali

 
 
%d blogger hanno fatto clic su Mi Piace per questo: